These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 10220121

  • 1. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.
    Massana J, Möller HJ, Burrows GD, Montenegro RM.
    Int Clin Psychopharmacol; 1999 Mar; 14(2):73-80. PubMed ID: 10220121
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
    Massana J.
    J Clin Psychiatry; 1998 Mar; 59 Suppl 14():8-10. PubMed ID: 9818624
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS).
    Keller M.
    Gen Hosp Psychiatry; 2001 Mar; 23(1):15-9. PubMed ID: 11226552
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
    Dubini A, Bosc M, Polin V.
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S49-55; discussion S71-3. PubMed ID: 9169310
    [Abstract] [Full Text] [Related]

  • 10. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial.
    Katona C, Bercoff E, Chiu E, Tack P, Versiani M, Woelk H.
    J Affect Disord; 1999 Oct; 55(2-3):203-13. PubMed ID: 10628889
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
    Nelson JC, Portera L, Leon AC.
    J Clin Psychiatry; 2005 Nov; 66(11):1409-14. PubMed ID: 16420078
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D, Bridgman K, Buis C.
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The antidepressant efficacy of reboxetine in patients with severe depression.
    Montgomery S, Ferguson JM, Schwartz GE.
    J Clin Psychopharmacol; 2003 Feb; 23(1):45-50. PubMed ID: 12544375
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.
    Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ, Comparative Efficacy Antidepressants Study Group.
    CNS Drugs; 2005 Feb; 19(2):137-46. PubMed ID: 15697327
    [Abstract] [Full Text] [Related]

  • 20. Reboxetine, the first selective noradrenaline reuptake inhibitor antidepressant: Efficacy and tolerability in 2613 patients.
    Versiani M.
    Int J Psychiatry Clin Pract; 2000 Feb; 4(3):201-8. PubMed ID: 24927454
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.